RT Journal Article
SR Electronic
T1 Chemoembolization in Colorectal Liver Metastases: The Rebirth
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 575
OP 584
VO 34
IS 2
A1 GIAMMARIA FIORENTINI
A1 CAMILLO ALIBERTI
A1 LUCA MULAZZANI
A1 PAOLO COSCHIERA
A1 VINCENZO CATALANO
A1 DAVID ROSSI
A1 PAOLO GIORDANI
A1 STEFANO RICCI
YR 2014
UL http://ar.iiarjournals.org/content/34/2/575.abstract
AB Currently image-guided trans-arterial chemoembolization (TACE) has a significant role in the therapy of patients with hepatocellular carcinoma and liver metastases. This endovascular hepatic-directed therapy offers the dual benefit of true local neoplastic control and reduction of side-effects. As a result, it has been included in the guidelines for primary liver cancer and is often considered as salvage therapy for patients liver metastases from neuroendocrine and chemorefractory colorectal tumors. The development of new embolizing agents, such as DC beads loaded with doxorubicin and irinotecan, permits better standardization and definition of protocols, making the procedures less linked to criteria of different hospitals and personal experiences of interventional radiologists. The understanding that hypoxia induces vessel re-growth will open a new avenue for clinical research and a rebirth for TACE. Chemoembolization followed by target therapy (bevacizumab, aflibercept and regorafenib) could increase quality, duration of responses and better quality of life.